Apeloa Pharmaceutical Co.,Ltd
000739
Kedudukan dalam Saham
#4338
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Harga Saham
$3.13
Modal Pasaran
$3.63B
Perubahan (1 hari)
-1.32%
Perubahan (1 tahun)
46.73%
Negara
CN
Perdagangan Apeloa Pharmaceutical Co.,Ltd (000739)
Kategori
Healthcare
Pendapatan untuk Apeloa Pharmaceutical Co.,Ltd (000739)
Pendapatan pada Jun 2026 TTM: $149.15M
Menurut laporan kewangan terkini Apeloa Pharmaceutical Co.,Ltd, pendapatan semasa syarikat ialah $149.15M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $170.18M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $146.72M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Apeloa Pharmaceutical Co.,Ltd dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $149.15M | -9.53% |
| 2024 | $164.85M | -3.13% |
| 2023 | $170.18M | 15.99% |
| 2022 | $146.72M | -16.29% |
| 2021 | $175.28M | 19.13% |
| 2020 | $147.13M | 61.66% |
| 2019 | $91.01M | 35.45% |
| 2018 | $67.19M | 28.72% |
| 2017 | $52.20M | 8.08% |
| 2016 | $48.30M | 26.97% |
| 2015 | $38.04M | -37.54% |
| 2014 | $60.90M | 79.55% |
| 2013 | $33.92M | 25.69% |
| 2012 | $26.99M | 83.30% |
| 2011 | $14.72M | 255.37% |
| 2010 | $4.14M | -25.11% |
| 2009 | $5.53M | 37.62% |
| 2008 | $4.02M | -6.10% |
| 2007 | $4.28M | -48.53% |
| 2006 | $8.32M | 30.32% |
| 2005 | $6.38M | 8.44% |
| 2004 | $5.89M | -2.73% |
| 2003 | $6.05M | -2.07% |
| 2002 | $6.18M | -300.22% |
| 2001 | $-3.09M | 423.46% |
| 2000 | $-589.59K | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
